Trial demonstrates potential of acoramidis for transthyretin amyloid cardiomyopathy
Acoramidis improves outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) compared with placebo, according to late breaking research presented in a Hot Line session today at ESC Congress 2023.
Aug 28, 2023
1
2